Posted by Michael Wonder on 30 Oct 2020
ICR welcomes NICE’s decision to reassess abiraterone acetate as first-line treatment for advanced prostate cancer
29 October 2020 - The Institute of Cancer Research, London, has welcomed the announcement by NICE that it will reconsider its decision not to recommend abiraterone as a first-line treatment for newly diagnosed, advanced prostate cancer.
An appeal panel today upheld a series of complaints from manufacturer Janssen, charities and prostate cancer specialists about NICE’s process in deciding not to make abiraterone available first-line.
